JV

Easterly Government Properties Completes Acquisition of VA - Columbus, the Seventh of 10 Properties in the VA Portfolio

Retrieved on: 
Monday, July 18, 2022
Defense, Health, Hospitals, Commercial Building & Real Estate, Construction & Property, REIT, Veterans, Acquisition, Government, Security (finance), Phrase, U.S. Securities and Exchange Commission, Forward-looking statement, NYSE, JV, Government agency, DEA, Annual report, Unitary state, GSA, Risk management, Easterly

Easterly owns, directly or through the JV, 94 properties totaling 9.1 million square feet.

Key Points: 
  • Easterly owns, directly or through the JV, 94 properties totaling 9.1 million square feet.
  • Easterly Government Properties, Inc. (NYSE:DEA) is based in Washington, D.C., and focuses primarily on the acquisition, development and management of Class A commercial properties that are leased to the U.S. Government.
  • For further information on the company and its properties, please visit www.easterlyreit.com .
  • This press release contains forward-looking statements within the meaning of federal securities laws and regulations.

RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis

Retrieved on: 
Monday, July 18, 2022
Research, SEC, Neurotrophic keratitis, Patent, Cytoprotection, Letter, Disease, OTCQB, Patient, Security (finance), Risk, U.S. Securities and Exchange Commission, Form 10-K, Time, Annual report, Private Securities Litigation Reform Act, Forward-looking statement, DED, Ophthalmology, Duane syndrome, Wound healing, HLB, Neurotrophic factors, Dry eye syndrome, JV, Company, CRO, Therapy, Regeneration, NK, FDA, SPA, Protocol, Clinical trial, Pharmaceutical industry, EU, Cenegermin

The FDA requires two successful phase 3 trials in most circumstances prior to submitting a new drug or biologics application (NDA/BLA).

Key Points: 
  • The FDA requires two successful phase 3 trials in most circumstances prior to submitting a new drug or biologics application (NDA/BLA).
  • The purpose of conducting simultaneous trials is to reduce the time required to complete phase 3.
  • Unlike dry eye disease, clinical studies for neurotrophic keratitis require a very simple and clear single primary endpoint, such as complete healing," according to HLBT.
  • The CRO, which signed the letter of intent with ReGenTree, a U.S. joint venture between RegeneRx and HLBT, participated in the clinical trial of Oxervate and has clinical experience and expertise in NK clinical trials.

Lifequest’s Wholly Owned Subsidiary Receives First Order for 93,000 Gallons/Day Industrial Wastewater Treatment Plant for a Pharmaceutical Company

Retrieved on: 
Wednesday, July 13, 2022
Zero, ETP, FOG, Company, Water quality, CEO, STP, GLOBE, JV, Founder, Sewage, DAF, Water

Through its wholly owned subsidiary, Biopipe India Private Limited, the Company is concurrently pursuing both industrial and sewage wastewater treatment with JV partner Abrimix.

Key Points: 
  • Through its wholly owned subsidiary, Biopipe India Private Limited, the Company is concurrently pursuing both industrial and sewage wastewater treatment with JV partner Abrimix.
  • Designed to be the primary treatment of a zero liquid discharge solution, the first treatment plant is to be established for a pharmaceutical company based out of Pune, India.
  • Lifequest offers effluent treatment plants (ETP), sewage treatment plants (STP), fat oil and grease (FOG) separator and hybrid media for water polishing.
  • The Abrimix ETP solution available through our joint venture is a highly efficient and cost-effective industrial wastewater treatment system that is vastly superior to Dissolved Air Floatation (DAF) and other onsite industrial wastewater treatment systems.

Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer

Retrieved on: 
Tuesday, July 12, 2022
SEC, Conference, Safety, Communication, Optimism, Therapy, Severe acute respiratory syndrome coronavirus 2, Company, Pneumonia, Patient, Parkinson's disease, Adult, OS, GLOBE, JV, Private Securities Litigation Reform Act, Cancer, Form 10-K, Gilead, Fibrosis, Risk, Forward-looking statement, Annual report, Pharmaceutical industry, Remdesivir

Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers.

Key Points: 
  • Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers.
  • Oncotelic has rare pediatric designation for DIPG (OT-101) through its 45% joint venture, melanoma (CA4P), and AML (OXi 4503).
  • Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine.
  • OT-101 has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer.

GALIANO GOLD PROVIDES METALLURGICAL AND OPERATIONAL UPDATE AT ASANKO GOLD MINE

Retrieved on: 
Friday, July 8, 2022
Efficiency, Water, LOM, Acquisition, JSE, Information, TSX, Investment Industry Regulatory Organization of Canada, Weather, Legislation, JV, Resource management, Climate change, Workforce, Gold Fields, Disagreement, COVID-19, Public expenditure, Company, Gold, Galiano, Phrase, Employment, Mining, Toronto Stock Exchange, Compliance, Infection, NYSE, Bureau Veritas, Health, Social responsibility, AGM, Risk, Time, Safety, AMEX, News, Program, Multimedia, Forward-looking statement, GFI, Copper, Risk management, BC

VANCOUVER, BC, July 8, 2022 /PRNewswire/ - Galiano Gold Inc. ("Galiano" or the "Company") (TSX: GAU) (AMEX: GAU)provides an update on metallurgical test work and plant recoveries at the Asanko Gold Mine ("AGM"), located in Ghana, West Africa.

Key Points: 
  • VANCOUVER, BC, July 8, 2022 /PRNewswire/ - Galiano Gold Inc. ("Galiano" or the "Company") (TSX: GAU) (AMEX: GAU)provides an update on metallurgical test work and plant recoveries at the Asanko Gold Mine ("AGM"), located in Ghana, West Africa.
  • The AGM is a 50:50 joint venture ("JV") with Gold Fields Ltd (JSE: GFI)(NYSE: GFI) which is managed and operated by Galiano.
  • As previously announced on February 25, 2022, the Company reported that the AGM experienced lower than expected recoveries in Q1 2022 (see news release "Galiano Gold Reports Lower than Expected Gold Recovery at the Asanko Gold Mine").
  • The Company currently operates and manages the Asanko Gold Mine, located in Ghana, West Africa which is jointly owned with Gold Fields Ltd.

Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions

Retrieved on: 
Thursday, July 7, 2022
Wearables, Mobile Technology, Mobile, Wireless, Technology, Neurology, Biometrics, Biotechnology, Physical Therapy, General Health, Robotics, Health, Insurance, Centers for Medicare & Medicaid Services, Patient, JV, CMS, Marketing, Center, COVID-19, Stroke, Sale, Company, Advertising, U.S. Securities and Exchange Commission, ALS, Annual report, Lists of diseases, CVA, Security (finance), EMG, Private Securities Litigation Reform Act, NYSE, Brachial plexus injury, Arm, Risk, Neuromuscular disease, Medicare, Coronavirus, Commission, Pharmaceutical industry, Video game, Health insurance, Risk management

Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter.

Key Points: 
  • Myomo, Inc. (NYSE American: MYO) (Myomo or the Company), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter.
  • Revenue for the second quarter of 2022 is expected to be $3.4 million to $3.6 million, an increase of 10% to 16% compared with the second quarter of 2021.
  • All revenue in the second quarter of 2022 was product revenue, as the Company did not receive payment of the remaining license fee from its joint venture partner in China.
  • Also, Myomo expects to report more than 400 additions to its pipeline of prospective MyoPro patients, a quarterly record, which reflects continued success with its new marketing and advertising strategies.

SMEV's Nitro Holdings LLC Announces the Creation of Cravin' Poultry LLC and Signs Its First Retail Storefront to Sell Its Cravin' Crawfish Line

Retrieved on: 
Thursday, July 7, 2022
Crypto, Steroid, Chicken, Poultry, JV, GLOBE, Aquaculture, Company, RAS, LLC, Pond, BTC, NFT, Hydroponics, Facebook

The new venture will raise and sell Cornish Cross Chickens which are a hybrid chicken derived from Cornish chickens and White Rock chickens.

Key Points: 
  • The new venture will raise and sell Cornish Cross Chickens which are a hybrid chicken derived from Cornish chickens and White Rock chickens.
  • Our other venture, Cravin Crawfish, LLC has already sent well over a ton of crawfish to market since being formed just weeks ago.
  • Nitro Holdings, LLC, is an Aqua-Culture based company focused on Farming, Logistics with interest in expansion into Hydroponics & Aquaponics.
  • Nitro Digital LLC, A wholly owned subsidiary of Nitro Holdings, LLC, will focus on NFT, Crypto as well as possible JVs in the BTC/NFT sector.

SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility

Retrieved on: 
Thursday, July 7, 2022
TEL, Death, Annual report, Research, Agitation, Autism, JV, GLOBE, CBD, Central nervous system, Company, U.S. Securities and Exchange Commission, Mitochondrial membrane transport protein, Pain, Prevalence, World, Infection, Cancer, Status epilepticus, Tourette syndrome, Private Securities Litigation Reform Act, World Health Organization, Obligate carrier, Nasdaq, SEC, Risk, Human, THC, Intention, Drug discovery, Alzheimer's disease, Pharmaceutical industry

TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that its recently established joint venture ("JV"), MitoCareX Bio, launched its new dedicated, advanced facility for the discovery and development of anti-cancer drug candidates. The new state-of-the-art laboratory and research facility is based in Ness-Ziona Science Park in Israel.

Key Points: 
  • The new state-of-the-art laboratory and research facility is based in Ness-Ziona Science Park in Israel.
  • MitoCareX Bio focuses on investigating mitochondrial carriers that are crucial for cell viability.
  • In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter family.
  • MitoCareX Bio is currently developing its computationally based drug discovery capabilities to enable its planned virtual screening activities.

ASUR Announces Total Passenger Traffic for June 2022

Retrieved on: 
Wednesday, July 6, 2022
Cancún International Airport, JV, ADS, Grupo Aeroportuario del Sureste, ASUR, ASR, Partnership, LLC, FAA, NYSE, Rio Negro, Airport, Aerostar Airport Holdings, Airline

MEXICO CITY, July 6, 2022 /PRNewswire/ -- Grupo Aeroportuario del Sureste, S.A.B. de C.V.  (NYSE: ASR; BMV: ASUR), ASUR, a leading international airport group with operations in Mexico, the U.S. and Colombia, today announced that passenger traffic for June 2022 reached a total of 5.6 million passengers, 16.9% above the levels reported in Jun 2019.

Key Points: 
  • de C.V. (ASUR) is a leading international airport operator with a portfolio of concessions to operate, maintain and develop 16 airports in the Americas.
  • This comprises nine airports in southeast Mexico, including Cancun Airport, the most important tourist destination in Mexico, the Caribbean and Latin America, and six airports in northern Colombia, including Medellin international airport (Rio Negro), the second busiest in Colombia.
  • ASUR is also a 60% JV partner in Aerostar Airport Holdings, LLC, operator of the Luis Muoz Marn International Airport serving the capital of Puerto Rico, San Juan.
  • Headquartered in Mexico, ASUR is listed both on the Mexican Bolsa, where it trades under the symbol ASUR, and on the NYSE in the U.S., where it trades under the symbol ASR.

Liberty Global Schedules Investor Call for Second Quarter 2022 Results

Retrieved on: 
Wednesday, July 6, 2022
Technology, VoIP, Audio, Video, Telecommunications, Mobile, Wireless, Networks, Internet, Virgin Media, Liberty Global, Plume, Global, JV, ITV, United Kingdom, Formula, Technology, Arm, Investor relations, Lionsgate, NASDAQ, Webcast, Eastern Time Zone, VodafoneZiggo, UPC, Video game, Sunrise, Telenet

Liberty Global plc (Liberty Global or the Company) (NASDAQ: LBTYA, LBTYB and LBTYK) today announced plans to release its second quarter 2022 results on Thursday, July 28, 2022.

Key Points: 
  • Liberty Global plc (Liberty Global or the Company) (NASDAQ: LBTYA, LBTYB and LBTYK) today announced plans to release its second quarter 2022 results on Thursday, July 28, 2022.
  • You are invited to participate in its Investor Call, which will begin the following day at 09:00 a.m. (Eastern Time) on Friday, July 29, 2022.
  • In addition to the dial-in teleconference, a summary investor presentation and listen-only webcast will be available within the Investor Relations section of www.libertyglobal.com .
  • Liberty Global (NASDAQ: LBTYA, LBTYB and LBTYK) is a world leader in converged broadband, video and mobile communications services.